熱門資訊> 正文
Senseonics Eversense 365血糖监测仪在美国获得批准
2024-09-17 19:52
- Senseonics (NYSE:SENS) and its partner Ascensia Diabetes Care announced Tuesday that the U.S. FDA cleared their next-generation continuous glucose monitoring (CGM) system, Eversense 365.
- Accordingly, the fully implantable CGM device will be available in the U.S. for people with Type 1 and Type 2 diabetes aged 18 years and older.
- Eversense 365 is the world’s first one-year CGM system, and it is highly differentiated from short-term CGMs, the duo said.
- Ascensia, owned by Japanese medical device maker PHC Holdings Corporation (OTCPK:PHCCF), plans to begin the product’s U.S. launch in Q4 2024.
- “Extending sensor longevity to a full year, coupled with seamless device connectivity and a high level of accuracy, provides both freedom and peace of mind to patients living with diabetes,” said Senseonics (SENS) CEO Tim Goodnow.
- Senseonics (SENS) operates in the CGM market dominated by Medtronic (MDT), Abbott Laboratories (ABT), and Dexcom (DXCM).
More on PHC Holdings, Senseonics, etc.
- Senseonics Holdings, Inc. (SENS) Q2 2024 Earnings Call Transcript
- Historical earnings data for PHC Holdings Corporation
- Dividend scorecard for PHC Holdings Corporation
- Financial information for PHC Holdings Corporation
- Seeking Alpha’s Quant Rating on Senseonics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
